RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Shanghai Henlius Biotech Stock

Shanghai Henlius Biotech ROA 2024

Shanghai Henlius Biotech ROA

0.06

Ticker

2696.HK

ISIN

CNE100003N76

In 2024, Shanghai Henlius Biotech's return on assets (ROA) was 0.06, a -170.77% increase from the -0.08 ROA in the previous year.

Shanghai Henlius Biotech Aktienanalyse

What does Shanghai Henlius Biotech do?

Shanghai Henlius Biotech Inc. was founded in 2010 and has since focused on the development of innovative biopharmaceuticals. The company is headquartered in Shanghai, China and has additional locations in Taiwan, the USA, and Europe. The company has developed a wide portfolio of products that are manufactured based on monoclonal antibodies. These antibodies are produced in the human body and can recognize and attack diseased tissue, making them useful for the treatment of various diseases. Shanghai Henlius Biotech Inc.'s business model is based on an extensive research and development process, ranging from the discovery of a new drug to final product approval. The company utilizes advanced technologies and research facilities to develop innovative therapies. The company specializes in the development of biosimilars and novel biopharmaceuticals. Biosimilars are drugs that are structurally similar to already approved biopharmaceuticals but may differ in some characteristics, such as their precise molecular structure. The company has already launched several biosimilars on the market, including those for the treatment of gynecologic cancer, breast cancer, and rheumatoid arthritis. In addition to biosimilars, the company also focuses on the development of novel biopharmaceuticals. These drugs are typically used for the treatment of rare diseases or cancer where there are limited treatment options available. The company has developed several such products, including antibodies for the treatment of lung cancer and bladder cancer. Shanghai Henlius Biotech Inc. has successfully established itself in the Chinese market in recent years but also operates internationally. The company has partnerships with numerous companies in Asia, Europe, and the USA to distribute its products worldwide. Partners include well-known names such as Accord Healthcare, Sandoz, and Pfizer. Overall, Shanghai Henlius Biotech Inc. is a leading player in the biotechnology industry. The company specializes in the development of high-quality biopharmaceuticals and has the capability to develop and bring innovative therapies to the market. Its business model is based on extensive research and development processes, allowing the company to be innovative and successful in a highly competitive market. Shanghai Henlius Biotech ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROA Details

Understanding Shanghai Henlius Biotech's Return on Assets (ROA)

Shanghai Henlius Biotech's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Shanghai Henlius Biotech's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Shanghai Henlius Biotech's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Shanghai Henlius Biotech’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Shanghai Henlius Biotech stock

What is the Return on Assets (ROA) of Shanghai Henlius Biotech this year?

The Return on Assets (ROA) of Shanghai Henlius Biotech is 0.06 undefined this year.

What was the ROA of Shanghai Henlius Biotech compared to the previous year?

The ROA of Shanghai Henlius Biotech has increased by -170.77% compared to the previous year.

What consequences do high ROA have for investors of Shanghai Henlius Biotech?

A high ROA is advantageous for investors of Shanghai Henlius Biotech, as it indicates that the company efficiently utilizes its assets and generates good profits.

What are the consequences of low ROA for investors in Shanghai Henlius Biotech?

A low ROA can be unfavorable for investors of Shanghai Henlius Biotech as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.

How does an increase in the ROA of Shanghai Henlius Biotech affect the company?

An increase in ROA of Shanghai Henlius Biotech can be an indicator of improved efficiency in asset utilization and higher profitability.

How does a reduction in ROA of Shanghai Henlius Biotech impact the company?

A reduction in the ROA of Shanghai Henlius Biotech can be an indicator of lower asset efficiency and profitability.

What are some factors that can influence the ROA of Shanghai Henlius Biotech?

Some factors that can influence the ROA of Shanghai Henlius Biotech include revenue, operating costs, asset structure, and industry average.

Why is the ROA of Shanghai Henlius Biotech important for investors?

The ROA of Shanghai Henlius Biotech is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.

What strategic measures can Shanghai Henlius Biotech take to improve ROA?

To improve ROA, Shanghai Henlius Biotech can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.

How much dividend does Shanghai Henlius Biotech pay?

Over the past 12 months, Shanghai Henlius Biotech paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Shanghai Henlius Biotech is expected to pay a dividend of 0 CNY.

What is the dividend yield of Shanghai Henlius Biotech?

The current dividend yield of Shanghai Henlius Biotech is .

When does Shanghai Henlius Biotech pay dividends?

Shanghai Henlius Biotech pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Shanghai Henlius Biotech?

Shanghai Henlius Biotech paid dividends every year for the past 0 years.

What is the dividend of Shanghai Henlius Biotech?

For the upcoming 12 months, dividends amounting to 0 CNY are expected. This corresponds to a dividend yield of 0 %.

In which sector is Shanghai Henlius Biotech located?

Shanghai Henlius Biotech is assigned to the 'Health' sector.

Wann musste ich die Aktien von Shanghai Henlius Biotech kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Shanghai Henlius Biotech from 12/12/2024 amounting to 0 CNY, you needed to have the stock in your portfolio before the ex-date on 12/12/2024.

When did Shanghai Henlius Biotech pay the last dividend?

The last dividend was paid out on 12/12/2024.

What was the dividend of Shanghai Henlius Biotech in the year 2023?

In the year 2023, Shanghai Henlius Biotech distributed 0 CNY as dividends.

In which currency does Shanghai Henlius Biotech pay out the dividend?

The dividends of Shanghai Henlius Biotech are distributed in CNY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Shanghai Henlius Biotech

Our stock analysis for Shanghai Henlius Biotech Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Shanghai Henlius Biotech Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.